These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 23535326

  • 1. Novel and highly potent histamine H3 receptor ligands. Part 3: an alcohol function to improve the pharmacokinetic profile.
    Labeeuw O, Levoin N, Poupardin-Olivier O, Calmels T, Ligneau X, Berrebi-Bertrand I, Robert P, Lecomte JM, Schwartz JC, Capet M.
    Bioorg Med Chem Lett; 2013 May 01; 23(9):2548-54. PubMed ID: 23535326
    [Abstract] [Full Text] [Related]

  • 2. The discovery of the benzazepine class of histamine H3 receptor antagonists.
    Wilson DM, Apps J, Bailey N, Bamford MJ, Beresford IJ, Briggs MA, Calver AR, Crook B, Davis RP, Davis S, Dean DK, Harris L, Heightman TD, Panchal T, Parr CA, Quashie N, Steadman JG, Schogger J, Sehmi SS, Stean TO, Takle AK, Trail BK, White T, Witherington J, Worby A, Medhurst AD.
    Bioorg Med Chem Lett; 2013 Dec 15; 23(24):6897-901. PubMed ID: 24161834
    [Abstract] [Full Text] [Related]

  • 3. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).
    Gao Z, Hurst WJ, Guillot E, Czechtizky W, Lukasczyk U, Nagorny R, Pruniaux MP, Schwink L, Sanchez JA, Stengelin S, Tang L, Winkler I, Hendrix JA, George PG.
    Bioorg Med Chem Lett; 2013 Jun 01; 23(11):3421-6. PubMed ID: 23591112
    [Abstract] [Full Text] [Related]

  • 4. Novel substituted pyrrolidines are high affinity histamine H3 receptor antagonists.
    Stocking EM, Aluisio L, Atack JR, Bonaventure P, Carruthers NI, Dugovic C, Everson A, Fraser I, Jiang X, Leung P, Lord B, Ly KS, Morton KL, Nepomuceno D, Shah CR, Shelton J, Soyode-Johnson A, Letavic MA.
    Bioorg Med Chem Lett; 2010 May 01; 20(9):2755-60. PubMed ID: 20382018
    [Abstract] [Full Text] [Related]

  • 5. Fluorinated non-imidazole histamine H3 receptor antagonists.
    Isensee K, Amon M, Garlapati A, Ligneau X, Camelin JC, Capet M, Schwartz JC, Stark H.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2172-5. PubMed ID: 19286376
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.
    Zeng Q, Rosenblum SB, Yang Z, Jiang Y, McCormick KD, Aslanian RG, Duguma L, Kozlowski JA, Shih NY, Hey JA, West RE, Korfmacher WA, Berlin M, Boyce CW.
    Bioorg Med Chem Lett; 2013 Nov 01; 23(21):6001-3. PubMed ID: 24050887
    [Abstract] [Full Text] [Related]

  • 7. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).
    Gao Z, Hurst WJ, Guillot E, Czechtizky W, Lukasczyk U, Nagorny R, Pruniaux MP, Schwink L, Sanchez JA, Stengelin S, Tang L, Winkler I, Hendrix JA, George PG.
    Bioorg Med Chem Lett; 2013 Jun 01; 23(11):3416-20. PubMed ID: 23591110
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and biological activity of novel tert-amylphenoxyalkyl (homo)piperidine derivatives as histamine H3R ligands.
    Kuder KJ, Łażewska D, Kaleta M, Latacz G, Kottke T, Olejarz A, Karcz T, Fruziński A, Szczepańska K, Karolak-Wojciechowska J, Stark H, Kieć-Kononowicz K.
    Bioorg Med Chem; 2017 May 15; 25(10):2701-2712. PubMed ID: 28372935
    [Abstract] [Full Text] [Related]

  • 9. Discovery of a new class of non-imidazole oxazoline-based histamine H(3) receptor (H(3)R) inverse agonists.
    Célanire S, Wijtmans M, Christophe B, Collart P, de Esch I, Dassesse D, Delaunoy C, Denonne F, Durieu V, Gelens E, Gillard M, Lallemand B, Lamberty Y, Lebon F, Nicolas JM, Quéré L, Snip E, Vanbellinghen A, Van Houtvin N, Verbois V, Timmerman H, Talaga P, Leurs R, Provins L.
    ChemMedChem; 2009 Jul 15; 4(7):1063-8. PubMed ID: 19405064
    [Abstract] [Full Text] [Related]

  • 10. Azole derivatives as histamine H3 receptor antagonists, part 2: C-C and C-S coupled heterocycles.
    Walter M, Isensee K, Kottke T, Ligneau X, Camelin JC, Schwartz JC, Stark H.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5883-6. PubMed ID: 20727744
    [Abstract] [Full Text] [Related]

  • 11. Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.
    Wilson DM, Apps J, Bailey N, Bamford MJ, Beresford IJ, Brackenborough K, Briggs MA, Brough S, Calver AR, Crook B, Davis RK, Davis RP, Davis S, Dean DK, Harris L, Heslop T, Holland V, Jeffrey P, Panchal TA, Parr CA, Quashie N, Schogger J, Sehmi SS, Stean TO, Steadman JG, Trail B, Wald J, Worby A, Takle AK, Witherington J, Medhurst AD.
    Bioorg Med Chem Lett; 2013 Dec 15; 23(24):6890-6. PubMed ID: 24269482
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and structure-activity relationship (SAR) study of 4-azabenzoxazole analogues as H3 antagonists.
    Shao N, Aslanian R, West RE, Williams SM, Wu RL, Hwa J, Sondey C, Lachowicz J, Palani A.
    Bioorg Med Chem Lett; 2012 Mar 01; 22(5):2075-8. PubMed ID: 22326166
    [Abstract] [Full Text] [Related]

  • 13. Discovery of novel lead in the group of N-substituted piperazine ether derivatives with potential histamine H3 receptor activity.
    Kuder KJ, Stachnik M, Schunack W, Szymańska E, Kieć-Kononowicz K.
    Med Chem; 2014 Mar 01; 10(6):588-99. PubMed ID: 24047214
    [Abstract] [Full Text] [Related]

  • 14. Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.
    Sadek B, Schwed JS, Subramanian D, Weizel L, Walter M, Adem A, Stark H.
    Eur J Med Chem; 2014 Apr 22; 77():269-79. PubMed ID: 24650714
    [Abstract] [Full Text] [Related]

  • 15. Azole derivatives as histamine H3 receptor antagonists, part I: thiazol-2-yl ethers.
    Walter M, von Coburg Y, Isensee K, Sander K, Ligneau X, Camelin JC, Schwartz JC, Stark H.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5879-82. PubMed ID: 20728354
    [Abstract] [Full Text] [Related]

  • 16. Clobenpropit analogs as dual activity ligands for the histamine H3 and H4 receptors: synthesis, pharmacological evaluation, and cross-target QSAR studies.
    Lim HD, Istyastono EP, van de Stolpe A, Romeo G, Gobbi S, Schepers M, Lahaye R, Menge WM, Zuiderveld OP, Jongejan A, Smits RA, Bakker RA, Haaksma EE, Leurs R, de Esch IJ.
    Bioorg Med Chem; 2009 Jun 01; 17(11):3987-94. PubMed ID: 19414267
    [Abstract] [Full Text] [Related]

  • 17. New lead elements for histamine H3 receptor ligands in the pyrrolo[2,3-d]pyrimidine class.
    Espinosa-Bustos C, Frank A, Arancibia-Opazo S, Salas CO, Fierro A, Stark H.
    Bioorg Med Chem Lett; 2018 Sep 15; 28(17):2890-2893. PubMed ID: 30025902
    [Abstract] [Full Text] [Related]

  • 18. Identification of Histamine H3 Receptor Ligands Using a New Crystal Structure Fragment-based Method.
    Frandsen IO, Boesgaard MW, Fidom K, Hauser AS, Isberg V, Bräuner-Osborne H, Wellendorph P, Gloriam DE.
    Sci Rep; 2017 Jul 06; 7(1):4829. PubMed ID: 28684785
    [Abstract] [Full Text] [Related]

  • 19. Discovery of novel steroidal histamine H3 receptor antagonists/inverse agonists.
    Ledneczki I, Tapolcsányi P, Gábor E, Éles J, Greiner I, Schmidt É, Némethy Z, Kedves RS, Balázs O, Román V, Lévay G, Mahó S.
    Bioorg Med Chem Lett; 2017 Oct 01; 27(19):4525-4530. PubMed ID: 28888822
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.
    Tao M, Raddatz R, Aimone LD, Hudkins RL.
    Bioorg Med Chem Lett; 2011 Oct 15; 21(20):6126-30. PubMed ID: 21906941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.